Hormonal
Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.
You can influence your GLP-1 levels naturally. Eating GLP-1-stimulating foods (meat, fish, salad) first, followed by a wait before carbs, improves glycemic control and weight loss. Gastrointestinal distension from bulky, low-energy-density foods also triggers beneficial GLP-1 secretion via vagal nerves without causing nausea.
In contrast, gut-derived GLP-1 primarily acts on GLP-1 receptors expressed on vagal sensory nerve terminals located near the intestines. The neural signals generated by this activation are selectively transmitted to specific brain regions, enabling the regulation of feeding behavior and glucose metabolism (insulin secretion and insulin action) without inducing adverse effects (Fig. 3).
Why this rating
Supported by animal studies and some human intervention studies on meal sequence and distension.
Source
Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity
Yuta Masuda et al. · Diabetology International · 2025
DOI 10.1007/s13340-025-00819-9
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.Strong
- Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →